Therapeutic applications of PARP inhibitors in ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic applications of PARP inhibitors in ovarian cancer

Published:2020-07 Issue: Volume:127 Page:110204
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Xie Hongyu,Wang Wenjie,Xia Bairong,Jin Weilin,Lou Ge

Funder

China Postdoctoral Science Foundation

Heilongjiang Province Postdoctoral Science Foundation

Special Fund in China Postdoctoral Science Foundation

National Nature Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference153 articles.

1. Advances in ovarian cancer therapy;Cortez;Cancer Chemother. Pharmacol.,2018

2. Exploring and comparing adverse events between PARP inhibitors;LaFargue;Lancet Oncol.,2019

3. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study;Matulonis;Am. Soc. Clin. Oncol.,2018

4. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial;Disis;JAMA Oncol.,2019

5. State-of-the-art strategies for targeting the DNA damage response in cancer;Pilié;Nat. Rev. Clin. Oncol.,2019

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prior authorization for FDA-approved PARP inhibitors in ovarian cancer;Gynecologic Oncology Reports;2024-04

2. MiR-5195-3p functions as a tumor suppressor by targeting RHBDD1 in ovarian cancer;HISTOL HISTOPATHOL;2023

3. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response;Journal of Ovarian Research;2023-11-22

4. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer;Scientific Reports;2023-11-10

5. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review;Cancers;2023-11-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3